RenovoRx Stock (NASDAQ:RNXT)
Previous Close
$1.15
52W Range
$0.77 - $2.35
50D Avg
$1.13
200D Avg
$1.18
Market Cap
$30.00M
Avg Vol (3M)
$60.52K
Beta
0.99
Div Yield
-
RNXT Company Profile
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
RNXT Performance
Peer Comparison
| Ticker | Company |
|---|---|
| KTTA | Pasithea Therapeutics Corp. |
| LGVN | Longeveron Inc. |
| NTRB | Nutriband Inc. |
| MNPR | Monopar Therapeutics Inc. |
| ADIL | Adial Pharmaceuticals, Inc. |
| IKNA | Ikena Oncology, Inc. |
| SABS | SAB Biotherapeutics, Inc. |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| VRAX | Virax Biolabs Group Limited |
| ELDN | Eledon Pharmaceuticals, Inc. |
| TPST | Tempest Therapeutics, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |